Material and Methods:
The VERO is an O ring system equipped with a gimbaled linac allowing pan and tilt rotations and with a stereoscopic dual-source kV X-ray imaging allowing the guidance of the tracking. A 4DCT is done to measure the range of the target movements with the breath: if the amplitude is < 7mm, an ITV is determined on the MIP images and if it is > 7mm, the DT method is preferred. A gold marker (Visicoil, IBA) is then implanted in the lesion and a new 4DCT is realized 1 week later. The GTVDT is drawn on the exhale phase and the PTVDT is defined with a 5mm margin. The dose is prescribed on the isodose covering 95 % of the PTV (Monte Carlo): the peripheral tumors receive 3x17 Gy, near the thoracic wall 4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic diseases received 5x10 Gy. For DT, treatments are delivered with 6-8 no coplanar beams.
Results: 77 patients were treated with lung SBRT, including 22 patients treated with DT. Among these 22 patients, the PTVITV was however estimated: the average size of the PTVDT was 28.8cc(6.5 -14.3 cc) and that of the PTVITV was 46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV volume. The average session length in DT was 35 min, the same as with the ITV method. The breathing rate of the patients was often irregular during the session and especially compared with the reference 4DCT. It did not affect the treatment delivery neither the guidance of the tracking. The clinical tolerance during and after the SBRT with tracking was excellent: 1 patient that was already treated for interstitial pulmonary fibrosis developed symptomatic radiation pneumonitis (RP). 5 other patients had radiological RP on the CT done during their first 6 months follow up period ; all of them received corticosteroid therapy and did not show any symptoms. There was no chest wall toxicity. Over a 16 months follow-up,1 patient did not benefit from treatment with DT SBRT and had a progressive disease.
Conclusion:
With a 40% reduction of the PTV, this DT technique makes it easy to monitor all the patients breathing motion, including very irregular rates, in a treatment time equivalent to more classical techniques based on the ITV.
EP-1223
Local failure after radical radiotherapy of NSCLC in relation to the pre-therapeutic PET/CT M. Kandi Purpose or Objective: Local failure in lung cancer is associated with extremely poor survival. This study tested whether the pattern of failure is associated with the most PET avid volume in the pre-therapeutic PET/CT scan.
Material and Methods:
Patients with inoperable NSCLC treated in our department between 2008 and 2010 were reviewed. Forty patients, who received radiotherapy (RT) for NSCLC and had an accessible pre-therapeutic FDG PET/CT scanning, were included. Fifteen of the patients developed local failure as the first event. Patient and tumour characteristics for patients with recurrences are presented in Table 1 . The peak SUV area in the pre-therapeutic PET/CT scan in both tumor and lymph nodes were identified by an experienced nuclear physician who delineated the volume encompassing 50% of the maximum SUV (SUVmax50) in all fifteen patients. All patients were followed by CT scans every third month. The CT scans which showed recurrences (rCT) were imported to the Eclipse treatment planning system (Varian MS) and the recurrence gross tumor volume(s) (rGTV) was delineated. A rigid registration between pre-therapeutic PET/CT and treatment planning CT (pCT) was performed using a soft tissue match on the tumor or the lymph nodes in SmartAdapt (Varian MS). The SUVmax50 volumes were copied to pCT using the rigid registration. The rCT with the defined rGTV were also fused with the pCT using a rigid registration based on normal tissue nearby the rGTV but excluding the rGTV. The vertebral column or the aortic arch was found to be preferable. Two radiation oncologists assessed the rigid registration between pCT and rCT.
Results:
The patients received conventionally fractionated RT with a total dose of 60-66 Gy. Planning target volumes (PTV) ranged from 169 cm3 to 1065 cm3 (mean = 678 cm3). Median time to local progression was seven months (95% CI 5-9 months). In twelve patients, the recurrences of the primary tumor appeared inside the PTV. In three cases, the recurrences were both inside and outside the PTV. These three recurrences outside the PTV appeared in mediastinal lymph node region. The rGTV overlapped with the pretherapeutic PET sub-volumes in twelve patients (Figure 1) . In one case, rGTV was near the PET sub-volume area without overlapping. In one patient, part of the target was missed because an atelectasis obscured the PET/CT signal and made the delineation of GTV less optimal.
Conclusion: This retrospective study shows that the SUVmax50 pre-therapeutic signal correlates with the posttherapeutic recurrences in the majority of patients. Pretherapeutic PET/CT or planning PET/CT is a useful tool to guide the future dose escalation studies.
EP-1224
An Australian radiotherapy decision support system with contextual justification M. Barakat Background: There is great potential to utilise a large range of retrospective clinical data as an evidence base in decision support systems (DSS) for cancer prognosis and subsequent personalised treatment decisions. Recently, there were several DSSs built for this purpose using machine learning tools, mainly regression models, Bayesian Networks (BN) and Support Vector Machines (SVM). These machine learning tools provide only a prediction of a class (decision), based on input attributes that were used to build the model, without providing additional information to clinicians about how and why this prediction was made. Objective: To investigate the performance of an alternative machine learning tool in building a lung cancer radiotherapy DSS that provides clinicians with an estimated prediction together with the influencing attributes and their values (evidence) in supporting the decision reached. This will provide contextual justification to clinicians regarding the decisions, which will further help them in deciding whether to adopt the machine prediction or not.
Material and Methods:
A Non-Small Cell Lung Cancer 2 year survival prediction model was built, using data at Liverpool Cancer Therapy Centre in NSW, Australia. The attributes used to predict the survival were age, gender, ECOG, GTV and FEV1. The machine learning tool used is a Decision Tree which automatically extracts rules from the training data and formulates these as if-then-else patterns. A report of the used rules during the prediction process indicates the effective attributes used to reach the decision. SVM, Regression models and BN were built and tested using the same data set; however, BN possess less, and SVM/Regression models possess none, of this reporting capability as they are learned by analysing probabilities and numerical distances among data points associated with prediction class.
Results:
The DSS was learnt within the Liverpool Clinic with an unfiltered cohort of 4650 4686 patients. After filtering out patient records with missing values for the used attributes the cohort was reduced to 97 patients treated radically. The area under curve of the Decision Tree, SVM, Regression Model and BN when tested using a rigorous 10 fold cross-validation method respectively was 0.62, 0.62, 0.63 and 0.6. There is no significant difference in the performance between the four tools examined, however, the decision tree also generates an understandable context with every prediction made as a list of supporting attributes like the example in Figure 1 .
Conclusion:
It is possible to build a DSS for NSCLC data that provides a prediction with additional information justifying the decision with similar performance as the commonly utilised SVM, BN and regression tools. To improve the performance and avoid over fitting, more diverse and complete training data is needed by incorporating data from other centres to the learning process using distributed learning.
EP-1225
MRI-defined GTV change during SBRT for unresectable or oligometastatic disease of the central thorax L. Henke 1 Purpose or Objective: Stereotactic body radiotherapy (SBRT) is an attractive modality for the definitive treatment of oligometastatic or unresectable primary lung malignancies. Proximity of the tumor to adjacent organs-at-risk (OAR) may limit delivery of a sufficiently ablative dose. The ability to adapt to tumor response during treatment may improve OAR sparing and/or allow dose escalation. This study aimed to evaluate the degree of daily interfractional variation in gross tumor volume (GTV) during SBRT for patients with oligometastatic or unresectable primary malignancy of the central thorax using a magnetic resonance image guided radiotherapy (MR-IGRT) treatment system.
Material and Methods:
Eleven patients with unresectable primary or oligometastatic malignancy of the central thorax were treated at our institution with extended fractionation SBRT on a clinical MR-IGRT system. Treatment regimens consisted of 60 Gy in 12 fractions (n= 8) or 62.5 Gy in 10 fractions (n=3). For each treatment fraction, low-field (0.35 Tesla) MR setup imaging was acquired as part of routine clinical practice. Daily GTV was retrospectively defined on MR image sets for all patients at each of 10 or 12 fractions, using initial GTVs from CT simulation as a template. Daily tumor volumes were then recorded and compared for each patient to evaluate for interfractional change in tumor volume.
